Aktienanalyse zu Profusa Inc (PFSA)PFSAProfusa Inc

Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery. It operates in the Healthcare sector.

Profusa Inc is not a good buy right now due to its significant financial losses and poor market performance. The stock has decreased by 99.61% year-to-date and has a current RSI of 38.82, indicating oversold conditions but also a lack of upward momentum. Furthermore, the company reported a net loss of $8.8 million for Q2 2026, which is a significant increase from the previous year's loss of $2.3 million, highlighting ongoing financial distress.